JE Vaccine Prevents Japanese Encephalitis

Japanese Encephalitis isn’t ONLY in Japan!

‍

As summer travel commences, healthcare providers should remain vigilant regarding Japanese Encephalitis Virus (JEV) risk for patients traveling to endemic regions. 

JEV infection that progresses to overt encephalitis carries high morbidity and mortality. Approximately 30% of patients with overt encephalitis succumb to the illness, and roughly 50% of survivors experience long-term neurologic, cognitive, or behavioral sequelae.  These patient testimonials document how profoundly life altering a JE infection can be.

Japanese Encephalitis is a vaccine-preventable disease. The inactivated Vero cell culture–derived JE vaccine, IXIARO (IXIARO)®, Japanese Encephalitis Vaccine, Inactivated, Adsorbed, is indicated for active immunization against JEV in individuals 2 months of age and older. The primary two-dose series must be completed at least one week prior to potential JEV exposure.

While the disease name suggests a localized threat, JEV is endemic throughout most of Asia and parts of the western Pacific, emphasizing a vast and geographically widespread area of risk.

Practices wishing to access waiting area support materials may request them via e-mail usmarketing@valneva.com.  Practices wishing to access the needed discounts on purchasing IXIARO JE Vaccine for their patients may do so through a free membership in PracticeWell Physician’s Buying Group.  Ordering IXIARO is easy, let the team at PracticeWell assist you in accessing it at the most favorable pricing.

‍